医学临床研究
  2025年4月9日 星期三           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2020, Vol. 37 Issue (2): 199-202    DOI: 10.3969/j.issn.1671-7171.2020.02.012
  论著 本期目录 | 过刊浏览 | 高级检索 |
异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响
陈宏伟, 杨孙虎
上海市第九人民医院普外科,上海 201999
Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer
CHEN Hong-wei, YANG Sun-hu
General Surgery Department of the Ninth People's Hospital of Shanghai, Shanghai 201999
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探究异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响。【方法】选择2014年8月至2017年5月在本院接受治疗的180例原发性肝癌患者作为研究对象。根据肝动脉化疗栓塞(TACE)术后保肝方案不同,分为A组(还原型谷胱甘肽+异甘草酸镁注射液)和B组(异甘草酸镁+丁二磺酸腺苷蛋氨酸)。比较两组患者治疗后血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、直接胆红素(DBIL)和总胆红素(TBIL)水平。观察两组患者治疗后不良反应发生情况。分析影响原发性肝癌患者预后的相关因素。【结果】治疗后,两组患者血清ALT、AST、DBIL和TBIL水平均较治疗前升高,差异有统计学意义(P<0.05)。B组患者治疗后血清ALT、AST、DBIL和TBIL水平均低于A组,差异有统计学意义(P<0.05)。A组患者胃肠道反应、白细胞减少、血红蛋白减少和血小板减少的发生率分别为26.44%、25.29%、20.69%和2.30%,B组患者胃肠道反应、白细胞减少、血红蛋白减少和血小板减少的发生率分别为24.73%、20.43%、16.13%和2.15%。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。A组患者平均生存时间为27.40(95%CI:25.22~29.59)个月,B组患者平均生存时间为30.27(95%CI:28.40~32.14)个月。两组患者3年生存时间比较,差异有统计学意义(P<0.05)。Cox单因素及多因素分析结果显示肿瘤数目、血管侵犯及保肝方案与原发性肝癌患者预后密切相关。【结论】异甘草酸镁联合丁二磺酸腺苷蛋氨酸保肝治疗能改善原发性肝癌患者TACE治疗后肝功能及其预后,值得临床推广。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
陈宏伟
杨孙虎
关键词 肝肿瘤栓塞,治疗性甘草酸/药理学    
Abstract【Objective】To explore the effect of magnesium isoglycate combined with ademetionine succinate on liver function and prognosis after interventional therapy for primary liver cancer.【Methods】One hundred and eighty patients with primary liver cancer who were treated in our hospital from August 2014 to may 2017 were selected as the study objects. According to the different schemes of liver protection after TACE, it was divided into two groups: group A (reduced glutathione + magnesium isoglycate injection) and group B (magnesium isoglycate + adenosylmethionine succinate). Serum ALT, AST, DBIL and TBIL levels were compared between the two groups. The adverse reactions of the two groups were observed to analyze the prognostic factors of patients with primary liver cancer.【Results】After treatment, the levels of ALT, AST, DBIL and TBIL in the two groups were significantly higher than those before treatment (P<0.05). The levels of ALT, AST, DBIL and TBIL in the group B were lower than those in the group A (P<0.05). The incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group A were 26.44%, 25.29%, 20.69% and 2.30% respectively; the incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group B were 24.73%, 20.43%, 16.13% and 2.15%, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The mean survival time of the group A was 27.40 (95% CI: 25.22~29.59) months, and that of the group B was 30.27 (95% CI: 28.40~32.14) months.There was significant difference between the two groups in the 3a survival time (P<0.05).Cox single factor and multi factor analysis showed that tumor number, vascular invasion and liver protection were closely related to the prognosis of patients with primary liver cancer.【Conclusion】Magnesium isoglycate combined with ademetionine succinate can improve the liver function and prognosis of patients with primary liver cancer after TACE treatment, which is worthy of clinical promotion.
Key wordsLiver Neoplasms    Embolization,Therapeutic    Glycyrrhizin/MT
收稿日期: 2019-05-19     
PACS:  R735.7  
通讯作者: E-mail:876206438@qq.com   
引用本文:   
陈宏伟, 杨孙虎. 异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响[J]. 医学临床研究, 2020, 37(2): 199-202.
CHEN Hong-wei, YANG Sun-hu. Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(2): 199-202.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.02.012     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I2/199
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn